PTH-analogs: Comparable or different?

Archives of Gerontology and Geriatrics

Volumn 49, Issue 2, 2009, Pages

  Verhaar, H J J ^a   Lems, W F ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone fracture; Osteoporosis; Parathyroid hormone; PTH analogs

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; PLACEBO; STRONTIUM RANELATE;

ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INCIDENCE; LEG CRAMP; LIMB PAIN; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RECOMBINANT PROTEINS;

EID: 67649687522     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2008.11.004     Document Type: Article

References (12)

1. Bogado C.E., Zanchetta J.R., Mango A., Fox J., and Newman M.K. Effects of parathyroid hormone 1-84 on cortical and trabecular bone at the hip as assessed by QCT: results at 18 months from the TOP study. J. Bone Miner. Res. (2005) 1083 (abstract)
2. Dempster D.W., Moreau I.A., Varela A., Smith S.Y., Ste Marie L.G., and Fox J. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months improves trabecular bone architecture: A study of iliac crest biopsies using computed tomography. J. Bone Miner. Res. (2005) F435 (abstract)
3. Greenspan S.L., Bone H.G., Ettinger M.P., Hanley D.A., Lindsay R., Zanchetta J.R., Blosch C.M., Mathisen A.L., Morris S.A., Marriott T.B., and Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146 (2007) 326-339
4. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., and Eriksen E.F. Teriparatide [recombinant human parathyroid hormone (1-34)] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 18 (2003) 1932-1941
5. Kurland E.S., Cosman F., McMahon D.J., Rosen C.J., Lindsay R., and Bilezikian J.P. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J. Clin. Endocrinol. Metab. 85 (2000) 3069-3076
6. Lems W.F., Hamdy N.A.T., and Netelenbos J.C. Teriparatide: an anabolic drug for the treatment of patients with osteoporosis. Ned. Tijdschr. Geneeskd. 150 (2006) 132-137
7. Lindsay R., Scheele W.H., Neer R., Pohl G., Adami S., Mautalen C., Reginster J.Y., Stepan J.J., Myers S.L., and Mitlak B.H. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Int. Med. 164 (2004) 2024-2030
8. McClung M.R., San Martin J., Miller P.D., Civitelli R., Bandeira F., Omizo M., Donley D.W., Dalsky G.P., and Eriksen E.F. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 165 (2005) 1762-1768
9. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., and Mitlak B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
10. Nevitt M.C., Chen P., Dore R.K., Reginster J.Y., Kiel D.P., Zanchetta J.R., Glass E.V., and Krege J.H. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos. Int. 17 (2006) 273-280
11. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perezm A., Kaufman J.M., Clancy A.D., and Gaich G.A. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18 (2003) 9-17
12. Prince R., Sipos A., Hossain A., Syversen U., Ish-Shalom S., Marcinowska E., Halse J., Lindsay R., Dalsky G.P., and Mitlak B.H. Sustained nonvertebral fragility fracture risk reduction after discontinuation of Teriparatide treatment. J. Bone Miner. Res. 20 (2005) 1507-1513